Open AccessA PROSPECTIVE STUDY OF HUMAN HERPESVIRUS-6 INFECTION IN RENAL TRANSPLANTATION
Author(s) -
Tetsushi Yoshikawa,
S. Suga,
Yoshizo Asano,
Toshihiko Nakashima,
Takehiko Yazaki,
Yoshinari Ono,
Tamio Fujita,
Kazuo Tsuzuki,
Satoshi Sugiyama,
Satoshi Oshima
Publication year - 1992
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-199211000-00022
Subject(s) - viremia , transplantation , medicine , kidney transplantation , kidney , virus , neutralizing antibody , antibody , titer , antibody titer , immunology , human herpesvirus 6 , herpesviridae , virology , viral disease
Sixty-five kidney transplant recipients and their (22 living related and 43 cadaveric) donors were studied prospectively to determine the relationship between kidney transplantation and human herpesvirus-6 (HHV-6) infection. The virus isolation from peripheral blood and other tissues and sequential determination of neutralizing antibodies to HHV-6 were performed during 3 months following the transplantation. All of the donors and their recipients examined had neutralizing antibodies to HHV-6 at the time of renal transplantation and the virus was not isolated from them. HHV-6 was isolated from 3 renal tissues (2 living related and 1 cadaveric) obtained during transplant surgery, but not from their blood at that time. HHV-6 viremia occurred in 9 (14%) of the 65 recipients around 2 to 4 weeks after the transplantation. An additional 27 recipients showed a significant rise in the antibody titer. Thus, the infection with HHV-6 was confirmed in 36 (55%) of the 65. These results indicate that the virus is activated in many cases in the early posttransplant period and that HHV-6 establishes in vivo latency in the kidney tissue. There was no correlation between HHV-6 infection and acute rejection or the antirejection prophylaxis.